Comparative one-month safety and effectiveness of five leading new-generation devices for transcatheter aortic valve implantation by Giordano, A. et al.
1Scientific RepoRtS |         (2019) 9:17098  | https://doi.org/10.1038/s41598-019-53081-w
www.nature.com/scientificreports
comparative one-month safety 
and effectiveness of five leading 
new-generation devices for 
transcatheter aortic valve 
implantation
Arturo Giordano1, Nicola corcione1, Paolo ferraro2, Alberto Morello1, Sirio conte2, 
Luca testa3, Francesco Bedogni3, Alessandro iadanza4, Sergio Berti5, Damiano Regazzoli6, 
Enrico Romagnoli  7, Carlo trani  7, Francesco Burzotta7, Martino pepe8, Giacomo frati9,10, 
Giuseppe Biondi-Zoccai  9,11* & The Registro Italiano GISE sull’impianto di Valvola Aortica 
Percutanea (RISPEVA) Study Investigators†
Transcatheter aortic valve implantation (TAVI) for aortic stenosis is becoming an appealing alternative 
to surgical aortic valve replacement in high-risk patients and to medical therapy for inoperable ones. 
Several new-generation TAVI devices have been recently introduced, but comparative analyses are 
lacking. We aimed to compare 1-month outcomes associated with such five leading new-generation 
TAVI devices exploiting data collected in the prospective observational RISPEVA (Registro Italiano GISE 
sull’impianto di Valvola Aortica Percutanea) Study. We queried the dataset of the ongoing RISPEVA 
study to retrieve baseline, procedural and 1-month outcome details of patients undergoing TAVI with 
Acurate, Evolut, Portico, Lotus, and Sapien3. Analysis was based on unadjusted and propensity score-
adjusted methods. We included 1976 patients, 234 (11.8%) treated with Acurate, 703 (35.6%) with 
Evolut, 151 (7.6%) with Lotus, 347 (17.6%) with Portico, and 541 (27.4%) with Sapien3. Unadjusted 
analysis for baseline features highlighted several significant differences, and other discrepancies were 
found for procedural features. Despite these differences, device and procedural success were similarly 
high (ranging from 98.0% to 99.4%, p > 0.05). However, procedural valve migration appeared more 
common with Acurate (p = 0.007), and major bleeding with Sapien3 (p = 0.002). Unadjusted analysis 
for 1-month outcomes also highlighted significant differences in the composite of death, stroke, 
myocardial infarction, major vascular complication, major bleeding, or renal failure (favoring Portico, 
p < 0.001), major vascular complications (favoring Lotus, p < 0.001), renal failure (favoring Portico, 
p = 0.035), and permanent pacemaker implantation (favoring Acurate, p < 0.001). Propensity score-
adjusted analyses showed lower rates of major adverse events with Evolut and Portico (p < 0.05), 
major vascular complications with Lotus and Portico (p < 0.05), renal failure with Sapien3 (p < 0.05) 
and permanent pacemaker implantation with Acurate (p < 0.05). In conclusion, new-generation TAVI 
devices have different profiles of early comparative safety and efficacy. These findings should be taken 
into account for individualized decision making and patient management.
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The management of aortic stenosis has been revolutionized by the introduction of transcatheter aortic valve 
implantation (TAVI) less than 20 years ago1. After the first pioneering efforts, several landmark trials using 
first-generation devices established the superiority of TAVI in comparison to medical therapy encompassing val-
vuloplasty in patients at prohibitive surgical risk and the non-inferiority of TAVI in comparison to surgical aortic 
valve replacement in subjects at high or intermediate risk, and, most recently, in low-risk patients2,3. Despite these 
breakthroughs, uncertainty persists on the long-term durability of TAVI and the precise impact of residual aortic 
regurgitation. Indeed, very long-term (>10 years) follow-up will be required to accurately gauge these risks1. 
Awaiting such strategic data, another area of controversy is the comparison between different TAVI devices.
While all new-generation devices boast important technological refiments including reduced size and skirt 
to minimize paravalvular leak, there are now at least 7 different TAVI devices available for clinical use1. Whereas 
Sapien3 is the only balloon-expandable valve, even among self-expandable devices, which include Acurate, 
Allegra, Evolut, JenaValve, Lotus, and Portico, differences abound4,5. For instance, manufacturers have diversified 
their products with alternative choices for device length, strut thickness, cell size, radial force, skirt length, and 
delivery method. To date, few comparative studies have been reported on TAVI devices. In particular, Vlaastra 
Feature Acurate Evolut Lotus Portico Sapien3 P
Patients 234 703 151 347 541 —
Age (years) 83.5 ± 6.0 82.1 ± 6.7 82.0 ± 6.5 82.5 ± 6.5 83.1 ± 6.5 0.015
Female gender 156 (66.7%) 391 (55.6%) 83 (55.0%) 223 (64.3%) 288 (53.2%) <0.001
Body mass index (kg/m2) 26.1 ± 4.5 26.1 ± 4.4 25.4 ± 3.9 26.8 ± 4.6 26.1 ± 4.6 0.045
Diagnosis <0.001
    Aortic stenosis 217 (92.7%) 593 (85.4%) 129 (85.4%) 291 (83.9%) 472 (87.3%)
    Mixed aortic valve disease 9 (3.9%) 76 (10.8%) 18 (11.9%) 15 (4.3%) 53 (9.8%)
Aortic regurgitation 5 (2.1%) 17 (2.4%) 1 (0.7%) 1 (0.3%) 2 (0.4%)
    Degenerated bioprosthesis 3 (1.3%) 17 (2.4%) 3 (2.0%) 40 (11.5%) 14 (2.6%)
Risk <0.001
    Inoperable 5 (2.1%) 45 (6.4%) 5 (3.3%) 6 (1.7%) 50 (9.2%)
    High 195 (83.3%) 618 (87.9%) 141 (93.4%) 278 (80.1%) 433 (80.0%)
    Intermediate 34 (14.5%) 40 (5.7%) 5 (3.3%) 63 (18.2%) 58 (10.7%)
Logistic EuroSCORE 12.9 ± 11.0 16.7 ± 11.6 16.3 ± 14.5 16.2 ± 11.6 16.7 ± 12.1 <0.001
EuroSCORE II 4.1 ± 4.2 5.0 ± 4.9 5.0 ± 6.1 4.2 ± 3.9 5.5 ± 4.8 <0.001
STS score 5.0 ± 3.8 5.6 ± 4.1 5.1 ± 4.2 6.3 ± 4.2 5.4 ± 4.2 0.054
New York Heart Association class <0.001
    I 1 (0.4%) 6 (0.9%) 5 (3.3%) 9 (2.6%) 13 (2.4%)
    II 70 (30.0%) 210 (31.8%) 35 (23.2%) 80 (23.1%) 187 (34.6%)
    III 159 (68.2%) 407 (61.6%) 104 (68.9%) 251 (72.3%) 323 (59.7%)
    IV 3 (1.3%) 38 (5.8%) 7 (4.6%) 7 (2.0%) 18 (3.3%)
Prior cardiac surgery 21 (9.0%) 38 (5.4%) 13 (8.6%) 22 (6.3%) 40 (7.4%) 0.276
Prior aortic valvuloplasty 12 (5.1%) 33 (4.7%) 13 (8.6%) 14 (4.0%) 52 (9.6%) 0.001
Pacemaker dependency 25 (10.7%) 50 (7.1%) 13 (8.6%) 31 (8.9%) 39 (7.2%) 0.407
Prior stroke or transient ischemic attack 21 (9.0%) 38 (5.4%) 13 (8.6%) 22 (6.3%) 40 (7.4%) 0.276
Estimated glomerular filtration rate (mL/
min) 65.1 ± 23.0 62.2 ± 23.8 66.5 ± 47.7 61.1 ± 24.8 62.6 ± 23.6 0.217
Left ventricular ejection fraction (%) 53 ± 11 52 ± 10 53 ± 12 54 ± 10 53 ± 10 0.424
Peak aortic gradient (mm Hg) 75.4 ± 21.3 76.4 ± 22.9 77.7 ± 23.4 71.4 ± 23.6 77.7 ± 20.9 0.014
Mean aortic gradient (mm Hg) 47.8 ± 13.8 47.3 ± 14.9 48.0 ± 14.8 48.0 ± 16.8 48.2 ± 13.8 0.896
Aortic valve area (cm2) 0.67 ± 0.23 0.67 ± 0.26 0.66 ± 0.24 0.69 ± 0.24 0.63 ± 0.18 0.040
Aortic regurgitation <0.001
None 89 (38.0%) 204 (29.0%) 45 (29.8%) 140 (40.4%) 124 (22.9%)
    1+ 96 (41.0%) 320 (45.5%) 71 (47.0%) 123 (35.5%) 302 (55.8%)
    2+ 36 (15.4%) 136 (19.4%) 29 (19.2%) 68 (19.6%) 103 (19.0%)
    3+ 13 (5.6%) 43 (6.1%) 6 (4.0%) 16 (4.6%) 12 (2.2%)
Porcelain aorta 8 (3.4%) 58 (8.3%) 9 (6.0%) 4 (1.2%) 49 (9.1%) <0.001
Angiographically significant coronary 
artery disease 62 (26.5%) 198 (28.2%) 34 (22.5%) 44 (12.7%) 140 (25.9%) <0.001
Iliofemoral tortuosity <0.001
    Mild 73 (64.0%) 121 (33.8%) 41 (49.4%) 100 (40.2%) 135 (47.2%)
    Moderate 39 (34.2%) 193 (53.9%) 40 (48.2%) 145 (58.2%) 127 (44.4%)
    Severe 2 (1.8%) 44 (12.3%) 2 (2.4%) 4 (1.6%) 24 (8.4%)
Table 1. Baseline features at unadjusted analysis.
3Scientific RepoRtS |         (2019) 9:17098  | https://doi.org/10.1038/s41598-019-53081-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
and colleagues showed that Sapien3 may be associated with lower surgical conversion rates, fewer strokes and 
permanent pacemaker implantations (PPI), but more bleedings than Evolut6, whereas Pagnesi et al. have reported 
similar short-term results with Acurate and Evolut4. Other comparative analyses have provided hints at other 
possible differences as well7–9. Of course, ongoing randomized trials will provide more accurate outcome data, 
but in the meanwhile, we aimed to inform clinicians and patients on the short-term comparative effectiveness 
and safety of 5 leading TAVI devices using the clinical data prospectively collected in the Registro Italiano GISE 
sull’impianto di Valvola Aortica Percutanea (RISPEVA) study10.
Feature Acurate Evolut Lotus Portico Sapien3 P
Patients 234 703 151 347 541 —
Local anesthesia 202 (86.3%) 594 (84.5%) 134 (88.7%) 313 (90.2%) 420 (77.6%) <0.001
Transephageal guidance 76 (32.5%) 10 (1.4%) 47 (31.1%) 128 (36.9%) 51 (9.4%) <0.001
Femoral access 216 (92.3%) 612 (87.1%) 141 (93.4%) 303 (87.3%) 510 (94.3%) <0.001
Percutaneous approach 208 (88.9%) 616 (87.6%) 130 (86.1%) 305 (87.9%) 464 (85.8%) 0.732
Sheathless procedure 5 (2.1%) 160 (22.8%) 4 (2.7%) 6 (1.7%) 26 (4.8%) <0.001
Sheath size (French) 18.4 ± 2.1 15.1 ± 1.7 18.4 ± 1.8 18.4 ± 0.7 14.5 ± 1.7 <0.001
Embolic protection device <0.001
   None 232 (99.2%) 702 (99.9%) 150 (99.3%) 345 (99.4%) 519 (95.9%)
   Claret 1 (0.4%) 1 (0.1%) 1 (0.7%) 2 (0.6%) 20 (3.7%)
   Shimon 1 (0.4%) 0 0 0 2 (0.4%)
Right ventricular pacing 118 (50.4%) 422 (60.0%) 60 (39.7%) 192 (55.3%) 452 (83.6%) <0.001
Predilation <0.001
   None 82 (35.0%) 272 (38.7%) 93 (61.6%) 117 (33.7%) 92 (17.0%)
   One balloon 149 (63.7%) 417 (59.3%) 58 (38.4%) 225 (64.8%) 449 (83.0%)
   Two balloons 3 (1.3%) 14 (2.0%) 0 5 (1.4%) 0
Balloon diameter (mm) 21.8 ± 2.9 20.4 ± 2.0 20.3 ± 1.9 20.7 ± 1.6 21.6 ± 2.0 <0.001
Balloon type <0.001
   Cristal 52 (34.2%) 19 (4.4%) 0 25 (10.9%) 7 (1.6%)
   Nucleus 3 (2.0%) 37 (8.5%) 7 (12.1%) 0 4 (0.9%)
   Z.Med 24 (15.8%) 72 (16.6%) 23 (39.7%) 1 (0.4%) 4 (0.9%)
   Other 73 (48.0%) 307 (70.6%) 28 (48.3%) 204 (88.7%) 434 (96.7%)
Prosthesis 0.029
   One 230 (98.3%) 681 (96.9%) 150 (99.3%) 340 (98.0%) 537 (99.3%)
   Two 4 (1.7%) 22 (3.1%) 1 (0.7%) 7 (2.0%) 4 (0.7%)
Heterogenous device 1 (0.4%) 0 0 0 0 0.114
Device size (French) 25.0 ± 2.1 28.1 ± 3.1 24.9 ± 2.0 26.4 ± 2.2 25.0 ± 2.4 <0.001
Pacing during implant 71 (30.3%) 152 (21.6%) 16 (10.6%) 18 (5.2%) 501 (92.6%) <0.001
Pacing rate (bpm) 181 ± 25 158 ± 36 145 ± 59 163 ± 24 182 ± 12 <0.001
Postdilation 111 (47.4%) 202 (28.7%) 2 (1.3%) 165 (47.6%) 27 (5.0%) <0.001
Balloon diameter (mm) 23.2 ± 1.9 24.1 ± 2.6 20 ± 0 23.9 ± 2.0 22.4 ± 2.1 <0.001
Balloon length (mm) 42.1 ± 4.7 40.8 ± 2.4 40.0 ± 0 41.1 ± 2.9 40.9 ± 7.4 0.415
Fluoroscopy time (seconds) 22.7 ± 13.5 26.3 ± 16.3 30.0 ± 11.0 26.4 ± 14.1 21.5 ± 14.8 <0.001
Procedural time (minutes) 120.5 ± 50.8 113.0 ± 51.5 104.5 ± 39.6 87.4 ± 43.1 113.1 ± 46.6 <0.001
Device success 232 (99.2%) 693 (98.6%) 148 (98.0%) 343 (98.9%) 533 (98.5%) 0.899
Procedural success 232 (99.2%) 693 (98.6%) 148 (99.4%) 345 (99.4%) 533 (98.5%) 0.627
Complications
   Death 1 (0.4%) 2 (0.3%) 3 (2.0%) 1 (0.3%) 6 (1.1%) 0.085
   Valve migration 5 (2.1%) 7 (1.0%) 0 0 1 (0.2%) 0.007
   Anulus rupture 0 0 0 0 2 (0.4%) 0.257
   Surgical conversion 0 1 (0.1%) 1 (0.7%) 2 (0.6%) 2 (0.4%) 0.576
   Coronary occlusion 0 1 (0.1%) 0 0 2 (0.4%) 0.590
   Myocardial infarction 0 1 (0.1%) 0 0 1 (0.2%) 0.873
   Pericardial tamponade 1 (0.4%) 2 (0.3%) 3 (2.0%) 2 (0.6%) 8 (1.5%) 0.069
   Aortic dissection 0 3 (0.4%) 0 3 (0.9%) 2 (0.4%) 0.492
   Major vascular complication 7 (3.0%) 25 (3.6%) 5 (3.3%) 11 (3.2%) 21 (3.9%) 0.969
   Major bleeding 8 (3.4%) 39 (5.6%) 5 (3.3%) 8 (2.3%) 43 (8.0%) 0.002
Table 2. Procedural features at unadjusted analysis.
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Methods
Design. The RISPEVA Study has been previously described in detail elsewhere10–12. Briefly, RISPEVA was a 
national prospective observational study focusing on TAVI conducted in several Italian centers. All methods were 
carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved 
by the institutional ethics committee of: Policlinico San Donato, San Donato Milanese, Milan; Pineta Grande 
Hospital, Castel Volturno; Policlinico Santa Maria alle Scotte, Siena; Fondazione C.N.R. G. Monasterio Ospedale 
del Cuore, Massa; Humanitas University, Rozzano;, Fondazione Policlinico Universitario A. Gemelli IRCCS, 
Rome; University of Catania, Catania; Spedali Civili di Brescia, Brescia; University of Pisa, Pisa; University of 
Turin, Turin; Ospedale Niguarda Ca’ Granda, Milan; Clinica Montevergine, Avellino; Centro Cardiologico 
Monzino, Milan; Anthea Hospital GVM Care&Research, Bari; Sapienza University of Rome-Policlinico Umberto 
I, Rome; “SS Antonio e Biagio e Cesare Arrigo” Hospital, Alessandria; Maria Pia Hospital, Turin; San Giovanni di 
Dio e Ruggi d’Aragona, Salerno; Ospedale di Lecco, Lecco; Azienda Ospedaliera Universitaria di Parma, Parma; 
Policlinico Universitario Mater Domini, Catanzaro; IRCCS San Martino, Genova; Ospedale Bolognini, Seriate; 
Ospedale Civile di Legnano, Legnano; Ospedale S. Chiara, Trento; Istituto Clinico San Rocco, Ome; Fondazione 
Poliambulanza, Brescia; Maria Cecilia Hospital, Cotignola; European Hospital, Rome (all in Italy). Written 
Feature Acurate Evolut Lotus Portico Sapien3 P
Patients 234 703 151 347 541 —
Clinical outcomes
   Major adverse event* 60 (25.6%) 135 (19.2%) 24 (15.9%) 40 (11.5%) 131 (24.2%) <0.001
   Death 4 (1.7%) 11 (1.6%) 4 (2.7%) 8 (2.3%) 8 (1.5%) 0.794
   Cardiac death 1 (0.4%) 4 (0.6%) 3 (2.0%) 2 (0.6%) 6 (1.1%) 0.357
   Surgical aortic valve replacement 0 1 (0.1%) 1 (0.7%) 3 (0.9%) 2 (0.4%) 0.320
   Valve thrombosis 0 2 (0.3%) 0 0 1 (0.2%) 0.742
   Valve degeneration 0 0 0 0 0 1
   Endocarditis 0 0 0 0 0 1
   Coronary occlusion 0 1 (0.1%) 0 0 2 (0.4%) 0.590
   Myocardial infarction 0 2 (0.3%) 0 0 2 (0.4%) 0.650
   Pericardial effusion 12 (5.1%) 27 (3.8%) 6 (4.0%) 8 (2.3%) 46 (8.5%) <0.001
   Stroke 1 (0.4%) 12 (1.7%) 4 (2.7%) 2 (0.6%) 7 (1.3%) 0.216
   Transient ischemic attack 0 2 (0.3%) 0 1 (0.3%) 0 0.618
   Stroke or transient ischemic attack 1 (0.4%) 13 (1.9%) 4 (2.7%) 3 (0.9%) 7 (1.3%) 0.283
   Major vascular complication 33 (14.1%) 61 (8.7%) 8 (5.3%) 17 (4.9%) 68 (12.6%) <0.001
   Amputation 0 0 0 0 0 1
   Major bleeeding 10 (4.3%) 20 (2.8%) 7 (4.6%) 9 (2.6%) 27 (5.0%) 0.218
   Renal failure 26 (11.1%) 63 (9.0%) 9 (6.0%) 16 (4.6%) 47 (8.7%) 0.035
   Permanent pacemaker 13 (5.6%) 122 (17.4%) 35 (23.2%) 42 (12.1%) 72 (13.3%) <0.001
Echocardiographic outcomes
   Left ventricular end-diastolic diameter (mm) 45.6 ± 9.3 49.2 ± 10.5 49.6 ± 8.1 46.7 ± 6.9 49.1 ± 8.5 0.002
   Left ventricular end-systolic diameter (mm) 32.1 ± 8.2 32.3 ± 10.5 33.2 ± 9.5 31.6 ± 8.0 32.1 ± 11.5 0.971
   Left ventricular ejection fraction (%) 55.2 ± 9.5 53.3 ± 9.6 52.9 ± 10.4 54.2 ± 9.1 53.2 ± 9.2 0.051
   Peak aortic gradient (mm Hg) 16.0 ± 9.5 15.3 ± 7.9 19.6 ± 14.0 18.2 ± 13.2 21.6 ± 11.5 <0.001
   Mean aortic gradient (mm Hg) 9.2 ± 0.4.4 8.2 ± 4.6 12.1 ± 5.4 9.4 ± 6.1 11.6 ± 5.1 <0.001
   Aortic valve area (mm2) 1.17 ± 0.47 1.43 ± 0.49 1.28 ± 0.37 1.04 ± 0.47 1.37 ± 0.47 <0.001
Aortic regurgitation <0.001
   None 44 (20.9%) 207 (35.3%) 91 (67.4%) 133 (44.5%) 240 (50.0%)
   1+ 135 (64.0%) 309 (52.7%) 40 (29.6%) 139 (46.5%) 224 (46.7%)
   2+ 32 (15.2%) 66 (11.3%) 4 (3.0%) 26 (8.7%) 16 (3.3%)
   3+ 0 4 (0.7%) 0 1 (0.3%) 0
   4+ 0 0 0 0 0
Mitral regurgitation <0.001
   None 12 (5.2%) 42 (7.0%) 6 (4.2%) 20 (6.0%) 21 (4.0%)
   1+ 131 (57.2%) 367 (61.0%) 87 (60.4%) 199 (59.8%) 263 (50.3%)
   2+ 64 (28.0%) 37 (6.2%) 42 (29.2%) 86 (25.8%) 193 (36.9%)
   3+ 15 (6.6%) 140 (23.3%) 8 (5.6%) 20 (6.0%) 36 (6.9%)
   4+ 7 (3.1%) 16 (2.7%) 1 (0.7%) 8 (2.4%) 10 (1.9%)
   Systolic pulmonary artery pressure (mm Hg) 36.7 ± 11.8 38.1 ± 15.0 38.2 ± 11.9 37.8 ± 11.0 35.5 ± 9.5 0.052
Table 3. One-month outcomes at unadjusted analysis. *Composite of death, stroke, myocardial infarction, 
major vascular complication, major bleeding, or renal failure.
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informed consent was obtained from all subjects. Additional details are also available in the online registration 
module on clinicaltrials.gov (NCT02713932).
Aims. The main aim of this RISPEVA subanalysis was to compare patients undergoing attempted implantation 
of Acurate, Evolut, Lotus, Portico, or Sapien3 devices, focusing on short-term (procedural, peri-procedural, and 
1-month) outcomes. Labelling was based on attempt to deliver and/or deploy a specific device, and not necessar-
ily on eventually successful implantation.
Patients, procedures, definitions. Details on patient and procedures in the RISPEVA Study have also 
been detailed previously. Briefly, all patients in whom TAVI was attempted at participating centers and willing to 
provide consent were offered inclusion in the study, without any additional selection criterion. Several baseline, 
procedural and outcome variables were collected in a dedicated electronic case report form. Procedural outcomes 
included: contrast volume, fluoroscopy time, procedural time, device success, procedural success, death, valve 
migration, anulus rupture, surgical conversion, coronary occlusion, myocardial infarction, pericardial tampon-
ade, aortic dissection, major vascular complication, and major bleeding. Follow-up assessments were planned at 
1 month after TAVI and subsequently. In particular, details on the following clinically relevant outcomes were 
systematically collected: death, cardiac death, surgical aortic valve replacement, valve thrombosis, valve degen-
eration, endocarditis, coronary occlusion, myocardial infarction, pericardial effusion, stroke, transient ischemic 
attack, major vascular complication, amputation, major bleeeding, renal failure, and PPI. Echocardiographic 
assessment was routinely performed at admission, at discharge, and at 1-month, focusing on the following end-
points: veft ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left 
ventricular ejection fraction (LEVF), peak aortic gradient, mean aortic gradient, aortic valve area, aortic regur-
gitation, mitral regurgitation, and systolic pulmonary artery pressure (SPAP). Major adverse events, a composite 
of death, stroke, myocardial infarction, major vascular complication, major bleeding, or renal failure, were also 
computed. All definitions originated by the current Valve Academic Research Consortium recommendations13.
Figure 1. Forest plot of propensity score-adjusted analysis for major adverse events (composite of death, stroke, 
myocardial infarction, major vascular complication, major bleeding, or renal failure).
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Statistical analysis. Continous variables are reported as mean ± standard deviation, and categorical varia-
bles as count (%). Unadjusted analysis was based on analysis of variance for continuous variables and chi2 test for 
categorical variables. Adjusted analysis was based on propensity score adjusted generalized linear models with 
default link for continuous variables and binomial likelihood for binary variables, using missing data imputa-
tion when appropriate. Pairwise propensity scores were generated using several baseline and procedural variables 
(Online supplement). Statistical significance for hypothesis testing was be set at the two-tailed 0.05 level, without 
multiplicity adjustment. Computations were performed with Stata 13 (StataCorp, College Station, TX).
Results
Baseline features. A total of 1976 patients were included, who underwent TAVI between 2012 and 2018, 
mostly in 7 high volume centers (Table S1): 234 (11.8%) treated with Acurate, 703 (35.6%) with Evolut, 151 
(7.6%) with Lotus, 347 (17.6%) with Portico, and 541 (27.4%) with Sapien3. Baseline features are provided in 
Table 1, with additional details in Table S1. Several differences in baseline features, with complex patterns in 
favor or against a given device, were found (Fig. S1). Specifically, there were significant differences in age, gender 
(with more females receiving Acurate and Portico), height, BMI, diagnosis, risk (with more inoperable patients 
receiving Evolut), Logistic EuroSCORE (with lower values in those receiving Acurate), EuroSCORE II, and STS 
score (all p < 0.05). Similarly, significant differences were found in NYHA class, prior valvuloplasty, peak aortic 
gradient, aortic valve area, aortic regurgitation, porcelain aorta, family history of CAD, hypertension, current 
smoking, prior CAD, angiographic CAD, prior acute pulmonary edema, prior myocardial infarction, prior percu-
taneous coronary intervention, syncope, carotid artery disease, peripheral artery disease, systolic blood pressure, 
diastolic blood pressure, hematocrit, oxygen dependency, prior cancer, LVEDV, LVESV, bicuspid aortic valve, and 
ilio-femoral tortuosity (all p < 0.05).
Procedural features. Procedural characteristics were also different in many domains (Table 2), including 
local anesthesia, transesophageal guidance, femoral access, sheathless procedure, sheath size, embolic protec-
tion device, right ventricular pacing, predilation, predilation balloon diameter, predilation balloon type, pros-
theses number, device size, pacing during implant, pacing rate, postdilation, postdilation balloon diameter, and 
Figure 2. Forest plot of propensity score-adjusted analysis for major vascular complication.
7Scientific RepoRtS |         (2019) 9:17098  | https://doi.org/10.1038/s41598-019-53081-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
postdilation balloon diameter (all p < 0.05). In particular, transesophageal guidance was less common with 
Evolut and Sapien3, smaller balloons were used with Lotus, pacing was more common with Evolut and Sapien3, 
and postdilation less prevalent with Lotus and Sapien3 (all p < 0.05). Despite such differences, procedural and 
device success were both very high, ranging between 98% and 99%, and non-significantly different across devices. 
Similarly, unadjusted procedural rates of death, anulus rupture, surgical conversion, coronary occlusion, myo-
cardial infarction, pericardial tamponade, aortic dissection, or major vascular complications were all similar (all 
p > 0.05), whereas valve migration was more common with Acurate, and major bleeding with Sapien3 (both 
p < 0.05).
Unadjusted analysis for one-month outcomes. Most one-month outcomes were similar across devices 
(Table 3), including death, cardiac death, surgical aortic valve replacement, valve thrombosis, valve degeneration, 
endocarditis, coronary occlusion, myocardial infarction, stroke, transient ischemic attack, amputation, and major 
bleeding (all p > 0.05). However, significant differences were found for major adverse events (p < 0.001, with low-
est rates for Portico), pericardial effusion (p < 0.001, with lowest rates for Portico), major vascular complication 
(p < 0.001, with lowest rates for Portico), and PPI (p < 0.001, with lowest rates for Acurate). Echocardiographic 
follow-up showed differences in LVEDD, peak aortic gradient, mean aortic gradient, aortic valve area, aortic 
regurgitation, and mitral regurgitation (all p < 0.05).
Adjusted analysis. Propensity score-adjusted analysis for selected endpoints is provided in Table S3. 
Specifically, major adverse events were fewest with Evolut (p = 0.040 vs Sapien3) and Portico (p = 0.016 vs 
Acurate) (Fig. 1), major vascular complications were less common with Evolut (p = 0.036 vs Lotus, p = 0.002 
vs Sapien3), Lotus (p = 0.024 vs Sapien3), and Portico (p = 0.040 vs Acurate, p = 0.010 vs Evolut) (Fig. 2), renal 
failure was less frequent with Sapien3 (p = 0.001 vs Acurate) (Fig. 3), and PPI was less common with Acurate 
(p = 0.002 vs Evolut, p < 0.001 vs Lotus, p = 0.043 vs Sapien3) (Fig. 4).
Adjusted analysis for echocardiographic features suggested lower mean aortic gradients with Acurate 
(p = 0.002 vs Lotus, p = 0.023 vs Sapien3), Evolut (p < 0.001 vs Lotus, p < 0.001 vs Sapien3), and Portico 
(p = 0.033 vs Lotus, p = 0.043 vs Sapien3), less aortic regurgitation ≥ 2 + /4+ with Sapien3 (p = 0.045 vs Acurate, 
Figure 3. Forest plot of propensity score-adjusted analysis for renal failure.
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p = 0.030 vs Evolut, p = 0.017 vs Portico) and Lotus (p = 0.025 vs Acurate), and less mitral regurgitation with 
Evolut (p = 0.017 vs Portico, p < 0.001 vs Sapien3) (Fig. 5).
Additional analysis. For exploratory purposes, we also appraised the impact of overall TAVI experience 
per center, as well as device-specific experience (Tables S4; S5). At unadjusted analysis using tertiles, instituions 
at high overall volume showed lower rates of major adverse events, death, and myocardial infarction than other 
centers (all p < 0.05), whereas PPI appeared less common in low volume institutions (p = 0.009). Device-specific 
experience did not seemed associated with significant differences in outcomes, with the notable exception of the 
risk of death with Lotus, which appeared higher in institutions less experienced with this device (p = 0.010).
Additional sensitivity inferential analyses were conducted forcing in the propensity score-adjusted model 
overall and device-specific experience (Table S6). These analyses, albeit limited by multiplicity issues, suggested 
that in more experienced settings Portico outperformed Acurate (p = 0.012) and Evolut proved better than 
Sapien3 (p = 0.045). Focusing on device-specific institutional experience, Portico proved better than Evolut in 
centers experienced with the latter device (p = 0.015), whereas in the same setting Evolut proved nonetheless 
better than Sapien3 (p = 0.025).
Discussion
Main findings. This analysis of the RISPEVA study focusing on short-term outcomes following TAVI with 5 
leading new-generation devices, despite its mainly descriptive and hypothesis-generating scope, has the following 
implications: (a) centers and operators performing TAVI used different devices based on preference, training, 
experience, and patient features; (b) despite substantial differences in baseline and procedural features, ranging 
from age and gender to subtleties such as pacing or transesophageal guidance, rates of device and procedural 
success, as well as those of several procedural outcomes including death, appeared largely similar with Acurate, 
Evolut, Lotus, Portico and Sapien3; (c) accordingly, one-month outcomes appeared quite similar across devices, 
with encouraging results in terms of death (<3% for all devices), as well as myocardial infarction, stroke and 
major bleeding; (d) differences were however apparent across devices for major vascular complications, renal 
failure and PPI; (e) propensity score-adjusted analysis confirmed such trends, highlighting that these devices may 
not be considered completely equivalent, and individualized decision making and device choice probably remain 
important to maximize the risk-benefit and cost-benefit profile of TAVI.
Figure 4. Forest plot of propensity score-adjusted analysis for permanent pacemaker implantation.
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The present findings appear important and timely, and supplement recent ones by other investigators who 
aimed at comparing different TAVI devices1. Overall, all recent reports reaffirm the safety of TAVI, confirming 
its established role in patients with aortic stenosis at intermediate to prohibitive surgical risk, and sustaining 
recent trials testing the role of TAVI in low risk patients2,3. Indeed, major adverse events were quite uncommon, 
despite this being a pragmatic registry without any specific selection or exclusion criteria. Yet, uncertainty per-
sists on the long-term durability of TAVI, especially in light of recent reports on valve deterioration and leaflet 
thrombosis (albeit typically silent)4–6. Indeed, structural valve degeneration occurred in 8.7% of patients receiv-
ing first-generation TAVI devices after a median follow-up of 5.8 years in the UK TAVI Registry, similar to the 
4.8% estimate provided after 6 years of follow-up in the Nordic Aortic Valve Intervention (NOTION) trial14,15. 
Accordingly, much emphasis must be given to the long-term comparative safety and efficacy of TAVI, especially 
when considering lower risk patients as potential candidates. Despite the ever accruing evidence base, operators 
are faced with novel devices or refinements of existing ones, with uncertainty on their incremental differences.
Context. Balloon-expandable devices have been originally considered superior to self-expandable devices 
in terms of PPI and aortic regurgitation rates, but were associated with higher rates of strokes and vascular com-
plications, at least in some series or comparisons16,17. More recent data support the existence of meaningful dif-
ferences between Evolut and Sapien, between Evolut and Portico, and possibly between Lotus and Sapien39,12. 
Furthermore, the temporary recall of Lotus depended on engineering issues likely of clinical impact, despite this 
device usefulness in minimizing aortic regurgitation, albeit at the potential expense of an increase in PPI rates. 
Other notices of caution or recalls have been recently issued for Sapien3. Thus, attentive focus on each device 
strenths and weaknesses is paramount. Indeed, in light of prior and recent comparative studies on new-generation 
TAVI devices as well as our own present ones, we may first infer that experienced operators who have confidence 
with a given device can obtain satisfactory results with any chosen product, but probably each institution should 
consider becoming familiar with at least two devices with different features, in order to maximize the benefit of 
individualized device choice, without compromising skills. Indeed, in keeping with our head-to-head compari-
sons, it appears that Portico and Evolut are associated with lower rates of major adverse events (p = 0.016 in favor 
of Portico when compared to Acurate; p = 0.040 in favor of Evolut when compared to Sapien3), Portico with 
Figure 5. Forest plot of propensity score-adjusted analysis for aortic regurgitation implantation ≥2+.
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fewer vascular complications (p < 0.05 in its favor when compared to Acurate and Evolut), Sapien3 with fewer 
renal failures (p = 0.001 in its favor when compared to Acurate), and Acurate with lower PPI rates (p < 0.05 in 
its favor when compared to Evolut, Lotus, and Sapien3). Echocardiographic analyses showed lower gradients 
with Acurate, Evolut and Portico, with aortic regurgitation and paravalvular leak appearing less common with 
Lotus and Sapien3. Notably, mean echocardiographic gradients appeared superior in self-expandable valves than 
in mechanically or balloon-expandable valves irrespective of valve-anulus-height, with potentially detrimental 
impact on long-term durability.
Focusing on institutional experience with TAVI in general and with specific devices, we found intriguing 
hypothesis-generating data, suggesting that clinical outcomes are better in higher volume centers, except for PPI, 
whose rates may indeed depend on local management protocols. Focusing on specific devices, only Lotus seemed 
significantly dependant on experience. Furthermore, we found that overall and device-specific experience did 
not dilute significant differences between devices, with persistent evidence that Portico outperformed Acurate 
and Evolut, with the latter still having an edge in comparison to Sapien3. Yet, these findings, while intriguing, 
need confirmation in long-term follow-up from RISPEVA and, most importantly, from ongoing comparative 
randomized trials1.
Limitations. On top of being limited by the non-randomized design, short-term follow-up, and reliance 
on propensity score adjustment, this study is limited by incomplete data collection for several ancillary baseline 
features such as frailty, absence of an imaging core lab, and lack of systematic endpoint adjudication. In addition, 
very few cases of TAVI with other devices such as JenaValve or Allegra were collected, and these devices were 
thus excluded from analysis. Notably, residual confounding cannot be excluded and might drive some important 
differences, even after propensity score adjustment, such as for vascular complications. In addition, while we 
attempted at exploring the impact of institutional experience with TAVI in general and with specific devices as 
well, operator volume and experience was not collected in the case report form, and thus could not be analyzed.
Conclusion
New-generation TAVI devices have different profiles of early comparative safety and efficacy. These findings 
should be taken into account for individualized decision making and patient management.
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